Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Researchers have begun scanning the first young athletes taking part in a new study using advanced brain imaging to explore the effects of head injuries in 11 to 18-year-olds.
Read more here.
The Swiss company’s over-the-counter wrist wearable, which uses optical sensors to gather blood pressure readings, will be available to U.S. consumers in 2026.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us